Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial)



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:11/9/2018
Start Date:August 2012
End Date:July 2024
Contact:Jami Maccombs
Email:jami.maccombs@abbott.com

Use our guide to learn which trials are right for you!

A Clinical Evaluation of the Safety and Effectiveness of the MitraClip® System for the Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects (COAPT Recruitment Closed). COAPT CAS (Recruiting)

The purpose of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial is to confirm
the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe
or severe functional mitral regurgitation (FMR) in Symptomatic Heart Failure Subjects who are
treated per standard of care and who have been determined by the site's local heart team as
not appropriate for mitral valve surgery. This randomized controlled trial will provide the
opportunity to strengthen or add labeling claims regarding safety and clinical benefits of
the MitraClip System for symptomatic heart failure patients with moderate-to-severe or severe
functional mitral regurgitation.

Approximately 610 subjects will be randomized at up to 100 investigational sites with
approximately 305 subjects targeted to receive the study device. COAPT study completed
recruiting subjects in June 2017.

As part of the COAPT trial, a subset of patients will be registered in the cardiopulmonary
exercise (CPX) sub-study. The objective of this sub-study is to evaluate the exercise
responses in a sub-cohort of COAPT subjects who receive MitraClip device (Device group)
compared to the Control group who do not receive MitraClip device. (Note: the CPX Sub-study
subjects will contribute to the analyses of the COAPT primary and secondary endpoints)

As an extension of the COAPT RCT trial, COAPT CAS study will be conducted after COAPT
enrollment is complete under the same investigational device exemption (IDE(G120024)). The
objective of this study is to evaluate the MitraClip® NT System for the treatment of
clinically significant functional mitral regurgitation (FMR) in symptomatic heart failure
subjects who are treated per standard of care and who have been determined by the site's
local heart team as not appropriate for mitral valve surgery. The anticipated study Primary
Completion date is July 2018 and the Study Completion Date is July 2024. COAPT CAS is
presently recruiting subjects.

Prospective, randomized, parallel-controlled, multicenter clinical evaluation of the
MitraClip device for the treatment of clinically significant functional mitral regurgitation
in symptomatic heart failure subjects who are treated per standard of care and who have been
determined by the site's local heart team as not appropriate for mitral valve surgery.
Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (Device group) or
to no MitraClip device (Control group).

As part of the COAPT trial, a subset of patients (at least 50 up to 100 in total) will be
registered in the CPX Sub-study, which is designed as a prospective, randomized (1:1 ratio to
the MitraClip or no MitraClip device), parallel-controlled, multicenter study registering
approximately 50-100 subjects in up to 50 qualified US sites from the COAPT trial. Subjects
registered and randomized in the CPX Sub-study will contribute to the total enrollment
approximately of 610 subjects in the COAPT trial. Roll-in subjects will not participate in
the CPX Sub-study.

The COAPT CAS study is designed as a prospective, multicenter, single arm, continued access
registry study. A maximum of 800 subjects (anticipated) will be registered from up to 75
sites in the United States. The enrollment will end once pre-market approval (PMA) of the
proposed expanded indication of MitraClip System is obtained. Active follow-up of patients
will be performed through 12 months with scheduled visits at 30 days and 12 months. The
national Trans catheter Valve Therapy Registry (TVT Registry) will be used for data
collection through 12 months. Annual follow-up data from 2 years through year 5 post-implant
will be obtained by linkage to the Centers for Medicare and Medicaid Services (CMS) Claims
database.

COAPT CAS data may be used to support the PMA application of the labeling claims for the
treatment of moderate to severe or severe FMR in symptomatic heart failure subjects. This
single arm registry will provide valuable new information regarding use of the MitraClip® NT
System under more "real world" conditions.

COAPT study completed recruiting subjects in June 2017. COAPT CAS is presently recruiting
subjects.

Inclusion Criteria:

1. Symptomatic functional MR (≥3+) due to cardiomyopathy of either ischemic or
non-ischemic etiology determined by assessment of a qualifying transthoracic
echocardiogram (TTE) obtained within 90 days and transesophageal echocardiogram (TEE)
obtained within 180 days prior to subject registration, with MR severity based
principally on the TTE study, confirmed by the Echocardiography Core Lab (ECL). The
ECL may request a transesophageal echocardiogram (TEE) to confirm MR etiology.

Note: Functional MR requires the presence of global or regional left ventricular wall
motion abnormalities, which are believed to be the primary cause of the MR. If a flail
leaflet or other evidence of degenerative MR is present, the subject is not eligible
even if global or regional left ventricular systolic dysfunction is present.

Note: Qualifying TTE must be obtained after the subject has been stabilized on optimal
therapy including Guideline Directed Medical Therapy (GDMT) and at least 30 days
after:

1. a greater than 100% increase or greater than 50% decrease in dose of GDMT

2. revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT
or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased
biventricular pacing (from <92% to ≥92%)

2. In the judgment of the HF specialist investigator at the site, the subject has been
adequately treated per applicable standards, including for coronary artery disease,
left ventricular dysfunction, mitral regurgitation and heart failure (e.g., with
cardiac resynchronization therapy, revascularization, and/or GDMT). The Eligibility
Committee must also concur that the subject has been adequately treated.

3. New York Heart Association (NYHA) Functional Class II, III or ambulatory IV.

4. The Local Site Heart Team (CT surgeon and HF specialist investigators) and the Central
Eligibility Committee concur that surgery will not be offered as a treatment option
and that medical therapy is the intended therapy for the subject, even if the subject
is randomized to the Control group.

5. The subject has had at least one hospitalization for heart failure in the 12 months
prior to subject registration and/or a corrected brain natriuretic peptide (BNP) ≥300
pg/ml or corrected n-Terminal pro- brain natriuretic peptide NT-proBNP ≥1500 pg/ml
measured within 90 days prior to subject registration ("corrected" refers to a 4%
reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg/m2 in BMI above a
reference BMI of 20 kg/m2).

Note: BNP or NT-proBNP must be obtained after the subject has been stabilized on GDMT
and at least 30 days after:

1. a greater than 100% increase or greater than 50% decrease in dose of GDMT

2. revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT
or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased
biventricular pacing (from <92% to ≥92%).

6. Left Ventricular Ejection Fraction (LVEF) is ≥20% and ≤50% within 90 days prior to
subject registration, assessed by the site using any one of the following methods:
echocardiography, contrast left ventriculography, gated blood pool scan or cardiac
magnetic resonance imaging (MRI).

Note: The method must provide a quantitative readout (not a visual assessment).

7. The primary regurgitant jet is non-commissural, and in the opinion of the MitraClip
implanting investigator can be successfully be treated by the MitraClip. If a
secondary jet exists, it must be considered clinically insignificant.

8. Creatine Kinase-MB (CK-MB) obtained within prior 14 days < local laboratory Upper
Limit of Normal (ULN).

9. Transseptal catheterization and femoral vein access is determined to be feasible by
the MitraClip implanting investigator.

10. Age 18 years or older.

11. The subject or the subject's legal representative understands and agrees that should
he/she be assigned to the Control group, he/she will be treated with medical therapy
and conservative management without surgery and without the MitraClip, either
domestically or abroad. If the subject would actively contemplate surgery and/or
MitraClip if randomized to Control, he/she should not be registered in this trial.

12. The subject or the subject's legal representative has been informed of the nature of
the trial and agrees to its provisions, including the possibility of randomization to
the Control group and returning for all required post-procedure follow-up visits, and
has provided written informed consent.

13. Left Ventricular End Systolic Dimension (LVESD) is ≤ 70 mm assessed by site based on a
transthoracic echocardiographic (TTE) obtained within 90 days prior to subject
registration.

For the CPX Sub-study: Subjects have to meet the COAPT study eligibility criteria to be
registered in the CPX Sub-study.

COAPT CAS study Inclusion Criteria:

1. Subjects must meet all of the above COAPT RCT inclusion criteria, and must have national
Medicare coverage by the Centers for Medicare and Medicaid Services (CMS).

Exclusion Criteria:

1. Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy
or chronic outpatient oral steroid use.

2. Untreated clinically significant coronary artery disease requiring revascularization.

3. Coronary artery bypass grafting (CABG) within 30 days prior to subject registration.

4. Percutaneous coronary intervention within 30 days prior to subject registration.

5. Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject
registration.

6. Tricuspid valve disease requiring surgery or transcatheter intervention.

7. Aortic valve disease requiring surgery.

8. Cerebrovascular accident within 30 days prior to subject registration.

9. Severe symptomatic carotid stenosis (> 70% by ultrasound).

10. Carotid surgery or stenting within 30 days prior to subject registration.

11. American College of Cardiology /American Heart Association (ACC/AHA) Stage D heart
failure.

12. Presence of any of the following:

- Estimated pulmonary artery systolic pressure (PASP) > 70 mm Hg assessed by site
based on echocardiography or right heart catheterization, unless active
vasodilator therapy in the cath lab is able to reduce the pulmonary vascular
resistance (PVR) to < 3 Wood Units or between 3 and 4.5 Wood Units with v wave
less than twice the mean of the pulmonary capillary wedge pressure

- Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive
pericarditis, or any other structural heart disease causing heart failure other
than dilated cardiomyopathy of either ischemic or non ischemic etiology

- Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)

- Hemodynamic instability requiring inotropic support or mechanical heart
assistance.

13. Physical evidence of right-sided congestive heart failure with echocardiographic
evidence of moderate or severe right ventricular dysfunction as assessed by site.

14. Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization
Therapy with cardioverter-defibrillator (CRT-D) within the last 30days prior to
subject registration.

15. Mitral valve orifice area < 4.0 cm2 assessed by site based on a transthoracic
echocardiogram (TTE) within 90 days prior to subject registration.

16. Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip
positioning on the leaflets or sufficient reduction in MR by the MitraClip. This
evaluation is based on transesophageal echocardiogram (TEE) evaluation of the mitral
valve within 180 days prior to subject registration and includes:

- Insufficient mobile leaflet available for grasping with the MitraClip device

- Evidence of calcification in the grasping area

- Presence of a significant cleft in the grasping area

- Lack of both primary and secondary chordal support in the grasping area

- Leaflet mobility length < 1 cm

17. Hemodynamic instability defined as systolic pressure < 90 mmHg with or without
afterload reduction, cardiogenic shock or the need for inotropic support or
intra-aortic balloon pump or other hemodynamic support device.

18. Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months.

19. Life expectancy < 12 months due to non-cardiac conditions.

20. Modified Rankin Scale ≥ 4 disability.

21. Status 1 heart transplant or prior orthotopic heart transplantation.

22. Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve,
or any prior transcatheter mitral valve procedure.

23. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

24. Active endocarditis or active rheumatic heart disease or leaflets degenerated from
rheumatic disease (i.e., noncompliant, perforated).

25. Active infections requiring current antibiotic therapy.

26. Subjects in whom transesophageal echocardiography (TEE) is contraindicated or high
risk.

27. Known hypersensitivity or contraindication to procedural medications which cannot be
adequately managed medically.

28. Pregnant or planning pregnancy within next 12 months.

Note: Female patients of childbearing age should be instructed to use safe
contraception (e.g. intrauterine devices, hormonal contraceptives: contraceptive
pills, implants, transdermal patches hormonal vaginal devices, injections with
prolonged release.

29. Currently participating in an investigational drug or another device study that has
not reached its primary endpoint. Note: Trials requiring extended follow-up for
products that were investigational, but have since become commercially available, are
not considered investigational trials.

30. Subject belongs to a vulnerable population per investigator's judgment or subject has
any kind of disorder that compromises his/her ability to give written informed consent
and/or to comply with study procedures.

For the CPX Sub-study: Subjects who have any contraindications to CPX and are not capable
of performing CPX per investigator's assessment should not be registered in the CPX
Sub-study.

COAPT CAS study Exclusion Criteria:

1. Subjects must not meet any of the above COAPT RCT exclusion criteria.
We found this trial at
82
sites
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Saibal Kar, MD
Phone: 310-423-3978
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
621 West Lombard Street
Baltimore, Maryland 21201
(410) 706-7101
Principal Investigator: Mark Vesley, MD
Phone: 410-328-5842
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Oluseun Alli, MD
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Igor Palacios, MD
Phone: 617-726-8424
?
mi
from
Boston, MA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Garrett Stewart, MD
Phone: 617-525-9573
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1000 Blythe Blvd
Charlotte, North Carolina 28203
(704) 355-2000
Principal Investigator: Michael J Rinaldi, MD
Phone: 704-355-4794
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Samir Kapadia, MD
Phone: 216-444-6697
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Gladwin Das, MD
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Principal Investigator: Samin Sharma, MD
Phone: 212-427-1540
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Howard C Herrmann, MD
Phone: 215-662-2180
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
22 Bramhall St
Portland, Maine 04102
(207) 662-0111
Principal Investigator: Joseph Wight, MD
Phone: 207-774-2642
Maine Medical Center One of the country's consistently highest rated hospitals is right in your...
?
mi
from
Portland, ME
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Saurabh Gupta, MD
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Thompson J Sullebarger
Phone: 813-353-1515
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
Principal Investigator: Steven Bolling, MD
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30309
Principal Investigator: Vivek Rajagopal, MD
Phone: 404-605-2800
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Principal Investigator: Vasilis Babaliaros, MD
Phone: 404-712-0131
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Osvaldo S Gigliotti, MD
?
mi
from
Austin, TX
Click here to add this to my saved trials
1 Cooper Plaza
Camden, New Jersey 08103
(856) 342-2000
Principal Investigator: Janah Aji, MD
Cooper University Hospital Cooper University Health Care, the clinical campus of Cooper Medical School of...
?
mi
from
Camden, NJ
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Daniel Steinberg, MD
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Jamie Kennedy, MD
Phone: 434-243-1000
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
251 E Huron St
Chicago, Illinois 60611
(312) 926-2000
Principal Investigator: Patrick McCarthy, MD
Phone: 312-695-4965
Northwestern Memorial Hospital Northwestern Memorial is an academic medical center hospital where the patient comes...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Clifford Kavinsky, MD
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
Principal Investigator: Ian Sarembock, MD
Phone: 513-585-1777
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Joshua Rovin, MD
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Juan Crestanello, MD
Phone: 614-293-8866
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Steven Yakubov, MD
Phone: 614-566-1250
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75226
Principal Investigator: Paul Grayburn, MD
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: Sarah Gualano, MD
Phone: 214-645-7500
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80262
Principal Investigator: Andreas Brieke, MD
Phone: 303-724-2102
?
mi
from
Denver, CO
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Magdi Ghali, MD
Phone: 515-633-3600
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Adam Greenbaum, M.D
Phone: 313-916-3875
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Andrew Wang, MD
Phone: 919-681-6197
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
2650 Ridge Ave.
Evanston, Illinois 60201
847.570.2000
Principal Investigator: Ted Feldman, MD
Evanston Hospital Evanston Hospital, opened in 1891, is the nucleus of the NorthShore University HealthSystem....
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Greenville, North Carolina 27834
Principal Investigator: Ramesh Daggubati, MD
?
mi
from
Greenville, NC
Click here to add this to my saved trials
80 Seymour St
Hartford, Connecticut 6102
(860) 545-5000
Principal Investigator: Raymond McKay, MD
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
(808) 538-9011
Principal Investigator: Christian Spies, MD
Phone: 808-691-8900
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Richard Smalling, MD, PhD
Phone: 713-500-6559
?
mi
from
Houston, TX
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Principal Investigator: Neal Kleiman, MD
Phone: 713-441-1100
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Principal Investigator: James Hermiller, MD
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Mark Wiley, MD
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Kansas City, Missouri 64111
Principal Investigator: Kenneth Huber, MD
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
La Jolla, California 92037
Principal Investigator: Matthew Price, MD
Phone: 858-554-9905
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lexington, Kentucky 40504
Principal Investigator: Robert Salley, MD
Phone: 859-977-0898
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Lincoln, Nebraska 68526
Principal Investigator: Omar Nass, MD
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Manhasset, New York 11030
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
Miami, Florida 33140
Principal Investigator: Nirat Beohar, MD
Phone: 305-674-2754
?
mi
from
Miami, FL
Click here to add this to my saved trials
800 E 28th St
Minneapolis, Minnesota 55407
(612) 863-4000
Principal Investigator: Mario Goessl, MD
Phone: 612-863-3900
Abbott Northwestern Hospital Our hospital has a long and proud history as a health care...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Missoula, Montana 59802
Principal Investigator: Mark Sanz, MD
Phone: 406-329-5615
?
mi
from
Missoula, MT
Click here to add this to my saved trials
Morristown, New Jersey 07962
Principal Investigator: Robert Kipperman, MD
Phone: 973-467-0005
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
2500 Grant Rd
Mountain View, California 94040
(650) 940-7000
Principal Investigator: Chad Rammohan, MD
El Camino Hospital El Camino Hospital is a nonprofit organization with hospital campuses in Mountain...
?
mi
from
Mountain View, CA
Click here to add this to my saved trials
5121 S Cottonwood St
Murray, Utah 84157
(801) 507-7000
Principal Investigator: Brian Whisenant, MD
Phone: 801-507-4700
Intermountain Medical Center Intermountain Medical Center is one of the most technologically advanced and patient-friendly...
?
mi
from
Murray, UT
Click here to add this to my saved trials
Nashville, Tennessee 37205
Principal Investigator: Evelio Rodriguez, MD
Phone: 615-222-5500
?
mi
from
Nashville, TN
Click here to add this to my saved trials
20 York St, N20 York St,
New Haven, Connecticut 06520
(203) 688-4242
Principal Investigator: John Forrest, MD
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Steven Jenkins, MD
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Cezar Staniloae, MD
Phone: 212-263-5656
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Chiu S Wong, MD
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Susheel Kodali, MD
Phone: 212-342-0444
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
Principal Investigator: Mohammad Ghani, MD
Phone: 405-608-3800
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orlando, Florida 32803
Principal Investigator: Andy Taussig, MD
Phone: 321-499-4178
?
mi
from
Orlando, FL
Click here to add this to my saved trials
3401 N Broad St
Philadelphia, Pennsylvania
(215) 707-2000
Principal Investigator: Howard Cohen, MD
Phone: 215-707-2230
Temple University Hospital On January 18, 1892 a three-story house at 3403 North Broad Street...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85006
Principal Investigator: Tim Byrne, DO
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Anson Jay C Smith, M.D.
Phone: 412-647-8117
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
9205 SW Barnes Rd
Portland, Oregon 97225
(503) 216-1234
Principal Investigator: Ethan Korngold, MD
Phone: 503-216-0900
Providence St. Vincent Medical Center Providence St. Vincent is renowned for its many centers of...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1250 E. Marshall St.
Richmond, Virginia 23298
(804) 828-9000
Virginia Commonwealth University Medical Center The Virginia Commonwealth University Health System is an urban, comprehensive...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Roanoke, Virginia 24033
Principal Investigator: Jason Foerst, MD
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Guy Reeder, MD
Phone: 507-255-0876
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Roslyn, New York 11576
Principal Investigator: Andrew D Berke, MD
?
mi
from
Roslyn, NY
Click here to add this to my saved trials
Royal Oak, Michigan 48073
Principal Investigator: George Hanzel, MD
Phone: 248-898-5242
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
2315 Stockton Blvd.
Sacramento, California 95817
(916) 734-2011
Principal Investigator: Jason Rogers, MD
Phone: 916-734-3764
University of California, Davis Medical Center UC Davis Medical Center serves a 65,000-square-mile area that...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: John Lasala, MD, PhD
Phone: 314-362-3729
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Jacob Mishell, MD
Phone: 415-833-6016
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1700 S Tamiami Trail
Sarasota, Florida 34239
(941) 917-9000
Principal Investigator: Ricardo Yaryura, MD
Phone: 941-917-2225
Sarasota Memorial Hospital Sarasota Memorial Health Care System, an 806-bed regional medical center, is among...
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Scottsdale, Arizona 85258
Principal Investigator: David G Rizik, MD
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Seattle, Washington 98122
Principal Investigator: John Peterson, MD
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Stanford, California 94305
Principal Investigator: Alan Yeung, MD
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Tallahassee, Florida 32308
Principal Investigator: Wayne Batchelor, MD
Phone: 850-216-0120
?
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Vancouver, British Columbia
Principal Investigator: Robert Boone, MD
?
mi
from
Vancouver,
Click here to add this to my saved trials
Washington, District of Columbia
Principal Investigator: Lowell Satler, MD
?
mi
from
Washington,
Click here to add this to my saved trials
3311 East Murdock Street
Wichita, Kansas 67208
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Wormleysburg, Pennsylvania 17043
Principal Investigator: Mubashir Mumtaz, MD
Phone: 717-231-8585
?
mi
from
Wormleysburg, PA
Click here to add this to my saved trials